aibioTravere sells $525 million of 2032 convertible notes to buy back $221 million of 2029 notes
Tickers TVTX
The 0.50% notes would lift convertible principal to $619.9 million but cut the coupon. Travere said it would spend about $350.9 million to repurchase part of the older debt.
Key facts
- Company
- Travere Therapeutics, Inc. (NASDAQ: TVTX)
- News type
- Debt Financing
- Primary source
- Travere Therapeutics (SEC 8-K)
Travere Therapeutics closed a $525.0 million sale of 0.50% convertible senior notes due 2032 on May 11 and said it will use part of the money to buy back $221.4 million of its 2.25% notes due 2029. The 8-K filing says the offering included $50.0 million of notes sold on the underwriters' full exercise of their over-allotment option.
The company priced the deal on May 6 at $475.0 million, upsized from the $400.0 million it first proposed. The notes carry an initial conversion price of about $64.90 a share.
The details
The 2032 notes pay interest of 0.50% a year, with the first payment on November 15, 2026, and mature on May 15, 2032. Holders can convert only in set circumstances, and Travere settles conversions in cash, shares or a mix at its election, per the proposal announcement. Travere cannot redeem the notes before May 21, 2029.
Travere estimated net proceeds at about $508.5 million after underwriting discounts and expenses, per the 8-K. It said it would spend about $350.9 million in cash, including accrued interest, to retire $221.4 million of 2029 note principal, well above the principal being retired.
By our arithmetic, estimated net proceeds of $508.5 million less the $350.9 million repurchase leave about $158 million. Of the $316.3 million of 2029 notes originally issued, about $94.9 million of principal would remain after the repurchase, by the same arithmetic.
Context
By our arithmetic, total convertible principal would rise to $619.9 million from $316.3 million: $525.0 million of 2032 notes plus the $94.9 million of 2029 notes that would remain. Annual cash interest on that debt would be about $4.8 million, against about $7.1 million on the old notes alone, because the new notes carry a much lower coupon.
The refinancing came weeks after FDA approval of FILSPARI in FSGS on April 13, as Travere was investing in the launch. In the first quarter the company reported cash and marketable securities of $264.7 million, before the notes.
The proposal announcement also warned that holders of the 2029 notes who had hedged their positions would likely buy stock at pricing, which the company said could raise the effective conversion price.
What it means for investors
Travere swapped a nearer maturity for a later one at a lower rate, took in about $158 million of net cash, and added about $300 million of principal. The cost is a larger debt load and the possibility of share dilution if the stock trades above the conversion price. The roughly $95 million of 2029 notes that would remain are a smaller tranche to deal with.
The company's first-quarter 10-Q says cash and operating cash flow should fund operations beyond the next 12 months, and that it may need to refinance debt before maturity.
What to watch
The first interest payment on the 2032 notes is due November 15, 2026. One conversion trigger, a share price above 130% of the conversion price, can apply only in calendar quarters that start after September 30, 2026, per the 8-K. The remaining 2029 notes mature on March 1, 2029.